Christopher Pearce - Chief Executive
Christopher Pearce has built the Group since inception and has been responsible for the formulation and implementation of strategy, collaborative and licensing agreements, and intellectual property. He was co-founder and Executive Chairman of Fitness First plc, the international fitness chain.
James Malthouse - Finance Director
James Malthouse joined the Group in 1993 and is a Chartered Accountant with banking and corporate finance experience. He was Chairman and Finance Director of Unigroup plc and Finance Director of Harcourt Group plc.
Dr. Ian Pike – Chief Operating Officer
Ian Pike has over 20 years’ experience working in the diagnostics and biotechnology sectors. Having gained a PhD in Medical Microbiology, he joined Wellcome Diagnostics as a research group leader and spent 8 years working on new diagnostic assays, particularly for hepatitis. In December 1999, he joined the Technology Transfer Office of the UK Medical Research Council with responsibility for patents and commercialisation of a wide portfolio of technologies related to the biomedical sector. Most recently, Ian worked for Cancer Research Ventures managing intellectual property and performing business development activities in Europe and the USA.
Glenn Barney – VP Business Development, USA
Glenn brings over 25 years of sales and business development experience with global life sciences companies, with strong biomarker focus. He was formerly VP Business Development at NextGen Sciences Inc. and held senior positions at Decision Biomarkers and Parkin Elmer Inc. Mr. Barney holds a BA in Biology from Boston University.
Dr. Rainer Voegeli – Commercial Director, Europe
Dr. Rainer Voegeli joined Proteome Sciences in September 2007 after being Head of Business Development at BioVisioN AG (later Digilab BioVisioN GmbH) where he concluded deals with many major pharmaceutical companies. Before moving into Biotechnology, he worked for ASTA Medica AG in research and business development positions in Germany and the USA. Rainer Voegeli qualified with a PhD in biochemistry at the University of Giessen, Germany and has developed considerable proteomics expertise in peptides and proteins.
Dr. Hans-Dieter Zucht – Chief Technical Officer, Proteome Sciences R&D, Frankfurt
Dr. Zucht came to Proteome Sciences in November 2008. He was Chief Technology Officer and Head of Bioinformatics at Biovision AG (Digilab Biovision GmbH) in Germany for 10 years. A biochemist by training, he worked from 1992 in molecular biology and peptide biochemistry at the Lower Saxony Institute of Peptide Research (later IPF pharmaceuticals) in Hanover, Germany. He is visiting professor at the Paris Lodron University in Salzburg, Austria.
Dr. Malcolm Ward – Chief Technical Officer, London Research Facility
Malcolm Ward joined Proteome Sciences plc in May 2001 having previously worked for GlaxoWellcome for 12 years, in protein mass spectrometry. He was involved in the establishment of the new leading edge protein separation and mass spectrometry facility at the Institute of Psychiatry, King’s College London. His research team is involved in biomarker discovery, validation and assay development. His academic qualifications include a Master of Science (MSc) in Molecular Biology from the University of Hertfordshire in 1996 and a Graduateship from the Royal Society of Chemistry (GRSC) in 1992. He obtained a PhD in Applied Proteomics at King’s College, London in 2009.
Dr. Josef Schwarz – Head of Projects/Production, Proteome Sciences R&D
Joseph Schwarz joined the Group in summer 2002 when Xzillion, the former proteomics division of Aventis Research and Technologies, was acquired by Proteome Sciences plc. He worked for Aventis/Hoechst Research and Technologies for 6 years, initially as head of mass spectrometry and later as research collaboration project leader. He was instrumental in the establishment of the integrated high throughput 2DE/mass spectrometry proteomics platform at the Frankfurt research facility. Josef Schwarz holds a PhD in organic chemistry/mass spectrometry from the Technical University of Berlin, Germany and a MBA from the University of Durham, UK. He is an author of a number of publications and co-inventor of patents.
